Official Title

Compassionate Use of Omegaven IV Fat Emulsion
  • Phase

    Phase 2
  • Study Type

  • Intervention/Treatment

    fish oil ...
  • Study Participants

This is a compassionate use protocol to use intravenous fish oil infusion, Omegaven®, to infants and children with parenteral nutrition-associated liver disease to enable reversal of elevated serum liver enzymes and direct bilirubin (cholestasis).
Intravenous lipids are necessary in PN (parenteral nutrition) dependent patients due to their high caloric value and essential fatty acid content. However, parenteral fat emulsions composed of soybean oils (omega 6 fatty acids) have been implicated in predisposing patients to PN associated liver disease.

It is hypothesized that by administering Omegaven®, comprised of fish oil (omega 3 fatty acids) in place of conventional soybean fat emulsion, the progression of PN-associated cholestasis may be prevented or reversed.
Study Started
Dec 31
Primary Completion
Feb 28
Study Completion
Feb 28
Results Posted
Feb 09
Last Update
Mar 10

Drug Omegaven

Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.

Omegaven Other

All subjects will receive Omegaven


Inclusion Criteria:

Two consecutive direct bilirubin levels of 2 mg/dl or more in a parenteral nutrition dependent infant or child (unable to meet nutritional needs solely by enteral nutrition)
Other causes of liver disease have been excluded. A liver biopsy is not necessary for treatment.
The patient must have utilized standard therapies to prevent the progression of the liver disease including reduction/removal of copper and manganese from daily PN, trial of enteral feeding if possible, and the use of ursodiol (i.e., Actigall®).

Exclusion Criteria:

Documented causes of chronic liver disease other than parenteral nutrition associated liver disease
Proven severe advanced liver disease including cirrhosis on biopsy, varices, ascites.
An allergy to any seafood product, egg protein, and/or previous allergy to Omegaven®
Active coagulopathy characterized by ongoing bleeding or by a requirement for clotting factor replacement (e.g. fresh frozen plasma or cryoprecipitate) to maintain homeostasis
Impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis
Unstable diabetes mellitus or hyperglycemia
Stroke, embolism, collapse and shock, recent MI
Cholestasis due to any reason other than parenteral associated liver disease
Active new infection at time of initiation of Omegaven®
Hemodynamic instability
The patient may not be enrolled in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team).



All Events

Event Type Organ System Event Term Omegaven

Level of Bilirubin

measurement of bilirubin level weekly. Available data reported.


Week 2 N=12

mg/dL (Mean)
Standard Deviation: 4.38

Week 3 N=8

mg/dL (Mean)
Standard Deviation: 4.39

Week 4 N=10

mg/dL (Mean)
Standard Deviation: 6.5

Week 8 N=11

mg/dL (Mean)
Standard Deviation: 4.81

Age, Continuous

days (Mean)
Full Range: 35.0 to 306.0

bilirubin level

mg/dL (Mean)
Standard Deviation: 4.14

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study